Hims & Hers Health rises after J.P. Morgan initiates coverage with 'overweight' rating

Hims & Hers Health

24/04/2026 09:44

** Telehealth firm Hims & Hers Health's HIMS.N shares rise 2.8% to $28.95 premarket after J.P. Morgan initiates HIMS coverage with "overweight"

** Novo partnership could mark a turning point, removing significant legal overhang and positioning co as a platform offering branded, generic, and compounded products - brokerage

** Co's weight loss specialty can still grow this year - J.P. Morgan

     ** Adds, more stable GLP-1 business, peptide legalization, revenue reacceleration in second half and potential for more branded partnerships creates compelling catalyst path against skeptical investor base

** Says HIMS still one of the most shorted stocks in S&P 400

** Brokerage keeps HIMS PT at $35, upside of 24% to its last close

** 12 of 17 brokerages rate stock "hold", 5 "buy"; median PT $24.5

** As of last close, shares down 13.3% YTD

 (Reporting by Utkarsh Hathi)

 ((utkarshtushar.hathi@thmsonreuters.com))